Related Experiment Video
Updated: Apr 26, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Feasibility of simultaneous integrated boost IMRT (SIB-IMRT) for castration-resistant prostate cancer
Tomoaki Hakariya1, Shiro Obata2, Tsukasa Igawa3
1Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan erbb2jp@yahoo.co.jp.
Aim:
We examined the feasibility of local intensity-modulated radiation therapy (IMRT) with pelvic irradiation using the simultaneous integrated boost (SIB) technique to treat patients with castration-resistant prostate cancer (CRPC) after several lines of hormonal therapy.
Patients And Methods:
Data from 10 consecutive patients with CRPC treated with SIB-IMRT between November 2001 and September 2009 were analyzed retrospectively.
Results:
A decline in prostate-specific antigen (PSA) level was observed in all cases after SIB-IMRT. Biochemical progression-free survival at 5 years was 70% with a median follow-up of 33.5 months after SIB-IMRT. All patients completed SIB-IMRT without delay due to acute toxicity. The PSA nadir after first-line hormonal therapy, the PSA before SIB-IMRT, the PSA doubling time before SIB-IMRT and the PSA nadir after SIB-IMRT were significant factors for biochemical progression after SIB-IMRT.
Conclusion:
SIB-IMRT for patients with CRPC is feasible and has a satisfactory effect in terms of disease control.
